INB-500
Undisclosed Cancers
PreclinicalDiscovery/Preclinical
Key Facts
About IN8bio
IN8bio is a leader in the clinical development of gamma-delta T cell therapies, a promising but challenging class of cellular immunotherapy. The company's core innovation is its DeltEx™ platform, which enables the genetic engineering and scalable manufacturing of γδ T cells, including its proprietary Drug Resistant Immunotherapy (DRI) approach designed to work in tandem with chemotherapy. With multiple clinical-stage assets, most notably INB-400 in a Phase 2 trial for glioblastoma, IN8bio is strategically positioned to address significant unmet needs in oncology, though its success hinges on clinical validation and navigating a complex competitive and financial landscape.
View full company profileTherapeutic Areas
Other Undisclosed Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Pritumumab-based ADC | Nascent Biotech | Discovery |
| Oncology Program | Grace Science | Discovery/Pre-clinical |